Organigram Global Inc. reported record quarterly revenue and adjusted EBITDA for the third quarter ended June 30, 2026, marking a significant operational milestone following its acquisition of Sanity Group GmbH. The Canadian cannabis leader posted net revenue of $105.8 million, a 49% increase from $70.8 million in the same period last year, while adjusted EBITDA more than doubled to $13.4 million from $5.7 million. This performance underscores the immediate financial impact of integrating Sanity Group, which contributed approximately €25 million (C$40 million) in net revenue since the deal closed on April 15, 2026.

The company’s bottom line saw a dramatic shift, turning from a net loss of $6.3 million in Q3 Fiscal 2025 to net income of $105.5 million in the current quarter. This profitability swing was primarily attributable to higher non-cash fair value gains on preferred shares, alongside improved net revenue and gross margins. Chief Executive Officer James Yamanaka noted that Sanity Group’s performance has met management expectations, reinforcing Organigram’s evolution into a global cannabis platform with integrated Canadian operations and a European distribution network.

Financial Performance Highlights

Operational efficiency improved alongside top-line growth, with adjusted gross margin expanding to 37% of net revenue ($39.1 million) from 34% ($24.2 million) in the prior-year period. This margin expansion was driven by a larger proportion of international sales from Sanity Group and better operational efficiencies in Canada. Selling, general, and administrative (SG&A) expenses rose to $32.7 million from $24.5 million due to increased marketing investments and acquisition-related amortization, but as a percentage of net revenue, SG&A decreased to 31% from 35%.

Cash flow dynamics reflected the company’s scaling efforts. Cash provided by operations before working capital changes turned positive at $6.2 million, up from $(0.7) million previously. However, net cash used in operating activities was $4.3 million, compared to cash provided of $14.6 million in Q3 Fiscal 2025, largely due to higher working capital investments required for increased business scale. Free cash flow resulted in an outflow of $3.9 million, contrasting with an inflow of $5.0 million in the prior year.

Strategic Developments and Leadership Changes

Sanity Group continues to execute its European growth strategy, advancing preparations for a Swiss recreational pilot project, progressing entry into Poland, and launching branded products in the UK through new strategic partnerships. The subsidiary also recorded its first meaningful medical cannabis sales in Switzerland during the quarter.

In leadership news, Paolo De Luca is departing Organigram after nine years of service as Chief Financial Officer and Chief Strategy Officer. De Luca played an instrumental role in several transformative transactions, including the Sanity Group acquisition. Greg Guyatt, who succeeded him as CFO, stated that the company remains on track for full-year Fiscal 2026 net revenue to exceed $350 million, with adjusted gross margin and adjusted EBITDA expected to surpass Fiscal 2025 performance levels.

What the Numbers Show

The divergence between net income and adjusted EBITDA highlights the significant impact of non-operating items on Organigram’s bottom line. While adjusted EBITDA grew robustly by 136%, reflecting strong core operational improvements from the Sanity integration, net income surged to $105.5 million largely due to non-cash fair value gains on preferred shares. Investors should note that while operational cash generation improved (pre-working capital cash flow turned positive), the substantial investment in working capital led to negative free cash flow, indicating that liquidity pressures may persist as the company scales its international footprint.

OrganiGram Holdings (NASDAQ: OGI) reported third-quarter sales of $76.413 million, exceeding the analyst consensus estimate of $67.660 million by 12.94 percent. The result marks a 49.41 percent year-over-year increase from $51.142 million in the same period last year, demonstrating strong top-line growth momentum for the cannabis producer.

The significant beat against market expectations suggests effective execution and robust demand during the quarter. For investors, surpassing estimates by nearly 13 percent indicates that OrganiGram Holdings is managing its operational dynamics better than anticipated, potentially strengthening its competitive position in the market.

Financial Performance Overview

The key financial metrics from the quarter highlight a substantial improvement in revenue generation compared to the prior year. The divergence between actual sales and analyst estimates underscores a positive shift in performance relative to market sentiment.

What the Numbers Show

The 49.41 percent year-over-year growth in sales is the most material takeaway from the filing. This substantial increase suggests that OrganiGram Holdings has successfully expanded its market presence or improved its pricing power compared to the previous year. While the source does not provide net profit or EBITDA figures, the revenue beat alone serves as a positive indicator of operational momentum. The fact that the company exceeded estimates by 12.94 percent further reinforces confidence in its current business trajectory.